25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

HLB Pharmaceutical Co. Ltd
Buy, Hold or Sell?

Let's analyze HLB Pharmaceutical Co. Ltd together

I guess you are interested in HLB Pharmaceutical Co. Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of HLB Pharmaceutical Co. Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about HLB Pharmaceutical Co. Ltd

I send you an email if I find something interesting about HLB Pharmaceutical Co. Ltd.

1. Quick Overview

1.1. Quick analysis of HLB Pharmaceutical Co. Ltd (30 sec.)










1.2. What can you expect buying and holding a share of HLB Pharmaceutical Co. Ltd? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
₩3,633.99
Expected worth in 1 year
₩4,541.54
How sure are you?
57.1%

+ What do you gain per year?

Total Gains per Share
₩907.55
Return On Investment
3.9%

For what price can you sell your share?

Current Price per Share
₩23,200.00
Expected price per share
₩15,940 - ₩25,750
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of HLB Pharmaceutical Co. Ltd (5 min.)




Live pricePrice per Share (EOD)
₩23,200.00
Intrinsic Value Per Share
₩61,164.29 - ₩74,283.63
Total Value Per Share
₩64,798.28 - ₩77,917.62

2.2. Growth of HLB Pharmaceutical Co. Ltd (5 min.)




Is HLB Pharmaceutical Co. Ltd growing?

Current yearPrevious yearGrowGrow %
How rich?$80.8m$61.2m$10.2m14.4%

How much money is HLB Pharmaceutical Co. Ltd making?

Current yearPrevious yearGrowGrow %
Making money-$623.9k-$4.1m$3.4m558.0%
Net Profit Margin-2.5%-17.7%--

How much money comes from the company's main activities?

2.3. Financial Health of HLB Pharmaceutical Co. Ltd (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of HLB Pharmaceutical Co. Ltd?

Welcome investor! HLB Pharmaceutical Co. Ltd's management wants to use your money to grow the business. In return you get a share of HLB Pharmaceutical Co. Ltd.

First you should know what it really means to hold a share of HLB Pharmaceutical Co. Ltd. And how you can make/lose money.

Speculation

The Price per Share of HLB Pharmaceutical Co. Ltd is ₩23,200. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of HLB Pharmaceutical Co. Ltd.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in HLB Pharmaceutical Co. Ltd, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩3,633.99. Based on the TTM, the Book Value Change Per Share is ₩226.89 per quarter. Based on the YOY, the Book Value Change Per Share is ₩-12.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of HLB Pharmaceutical Co. Ltd.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.010.0%-0.020.0%-0.130.0%-0.130.0%-0.100.0%
Usd Book Value Change Per Share-0.210.0%0.160.0%-0.010.0%0.110.0%0.090.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.210.0%0.160.0%-0.010.0%0.110.0%0.090.0%
Usd Price Per Share12.47-14.48-9.09-9.84-8.21-
Price to Earnings Ratio285.11-28.32-18.85-25.46-24.47-
Price-to-Total Gains Ratio-58.60--7.34-21.02-16.23-8.67-
Price to Book Ratio4.90-6.21-4.71-7.74-10.29-
Price-to-Total Gains Ratio-58.60--7.34-21.02-16.23-8.67-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share16.24
Number of shares61
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.160.11
Usd Total Gains Per Share0.160.11
Gains per Quarter (61 shares)9.696.58
Gains per Year (61 shares)38.7526.34
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10392902616
20786805342
3011610707968
40155146010594
501941850132120
602332240158146
702712630184172
803103020211198
903493410237224
1003883800263250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share2.02.00.050.0%4.08.00.033.3%7.013.00.035.0%9.019.00.032.1%9.019.00.032.1%
Book Value Change Per Share2.02.00.050.0%6.06.00.050.0%12.08.00.060.0%16.012.00.057.1%16.012.00.057.1%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.028.00.0%0.00.028.00.0%
Total Gains per Share2.02.00.050.0%6.06.00.050.0%12.08.00.060.0%16.012.00.057.1%16.012.00.057.1%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of HLB Pharmaceutical Co. Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---303.911226.887-234%-12.001-96%154.208-297%129.785-334%
Book Value Per Share--3633.9873215.614+13%2753.797+32%2081.809+75%1634.163+122%
Current Ratio--2.1831.704+28%1.106+97%1.277+71%1.455+50%
Debt To Asset Ratio--0.2670.327-19%0.400-33%0.452-41%0.473-44%
Debt To Equity Ratio--0.3630.499-27%0.668-46%0.908-60%0.971-63%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--524017702160.000608764191110.000-14%375365525777.500+40%417509819388.000+26%379438007159.643+38%
Eps--15.617-28.050+280%-184.572+1282%-189.242+1312%-142.542+1013%
Ev To Ebitda Ratio--infinfnan%infnan%infnan%infnan%
Ev To Sales Ratio--3.6624.457-18%2.977+23%5.551-34%15.253-76%
Free Cash Flow Per Share--83.105-67.530+181%-125.357+251%-361.928+536%-261.599+415%
Free Cash Flow To Equity Per Share--83.105-67.530+181%172.252-52%-94.584+214%-75.279+191%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--74283.631--------
Intrinsic Value_10Y_min--61164.290--------
Intrinsic Value_1Y_max---61.293--------
Intrinsic Value_1Y_min---64.617--------
Intrinsic Value_3Y_max--5535.546--------
Intrinsic Value_3Y_min--5169.220--------
Intrinsic Value_5Y_max--18028.130--------
Intrinsic Value_5Y_min--16240.961--------
Market Cap737282080000.000+23%565991114000.000657197992000.000-14%412893854500.000+37%446548239100.000+27%405907921714.286+39%
Net Profit Margin--0.014-0.025+282%-0.177+1375%-0.435+3237%-0.867+6346%
Operating Margin----0%-0%0.007-100%-0.5220%
Operating Ratio--1.3591.455-7%0.530+157%0.711+91%1.793-24%
Pb Ratio6.384+23%4.9016.214-21%4.711+4%7.742-37%10.292-52%
Pe Ratio371.394+23%285.10928.317+907%18.845+1413%25.456+1020%24.472+1065%
Price Per Share23200.000+23%17810.00020680.000-14%12992.500+37%14051.500+27%11730.179+52%
Price To Free Cash Flow Ratio69.792+23%53.57766.133-19%-30.959+158%-120.588+325%-90.823+270%
Price To Total Gains Ratio-76.338-30%-58.603-7.339-87%21.023-379%16.228-461%8.672-776%
Quick Ratio--1.2060.960+26%0.944+28%1.060+14%0.968+25%
Return On Assets--0.003-0.007+314%-0.040+1375%-0.053+1770%-0.045+1515%
Return On Equity--0.004-0.011+363%-0.067+1667%-0.120+2896%-0.101+2441%
Total Gains Per Share---303.911226.887-234%-12.001-96%154.208-297%129.785-334%
Usd Book Value--80840157.04171533199.661+13%61259821.431+32%46311049.405+75%36710441.198+120%
Usd Book Value Change Per Share---0.2130.159-234%-0.008-96%0.108-297%0.091-334%
Usd Book Value Per Share--2.5442.251+13%1.928+32%1.457+75%1.144+122%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--366812391.512426134933.777-14%262755868.044+40%292256873.572+26%265606605.012+38%
Usd Eps--0.011-0.020+280%-0.129+1282%-0.132+1312%-0.100+1013%
Usd Free Cash Flow--1848710.871-1502238.861+181%-2788636.403+251%-8051295.667+536%-5861727.629+417%
Usd Free Cash Flow Per Share--0.058-0.047+181%-0.088+251%-0.253+536%-0.183+415%
Usd Free Cash Flow To Equity Per Share--0.058-0.047+181%0.121-52%-0.066+214%-0.053+191%
Usd Market Cap516097456.000+23%396193779.800460038594.400-14%289025698.150+37%312583767.370+27%284135545.200+39%
Usd Price Per Share16.240+23%12.46714.476-14%9.095+37%9.836+27%8.211+52%
Usd Profit--347405.177-623999.362+280%-4105921.780+1282%-4215729.968+1313%-3198223.066+1021%
Usd Revenue--25041311.44924075629.737+4%23245149.317+8%15213578.023+65%11955194.876+109%
Usd Total Gains Per Share---0.2130.159-234%-0.008-96%0.108-297%0.091-334%
 EOD+3 -5MRQTTM+23 -12YOY+23 -125Y+25 -1110Y+26 -9

3.3 Fundamental Score

Let's check the fundamental score of HLB Pharmaceutical Co. Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15371.394
Price to Book Ratio (EOD)Between0-16.384
Net Profit Margin (MRQ)Greater than00.014
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.206
Current Ratio (MRQ)Greater than12.183
Debt to Asset Ratio (MRQ)Less than10.267
Debt to Equity Ratio (MRQ)Less than10.363
Return on Equity (MRQ)Greater than0.150.004
Return on Assets (MRQ)Greater than0.050.003
Total5/10 (50.0%)

3.4 Technical Score

Let's check the technical score of HLB Pharmaceutical Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.898
Ma 20Greater thanMa 5022,280.000
Ma 50Greater thanMa 10020,783.600
Ma 100Greater thanMa 20023,564.300
OpenGreater thanClose22,800.000
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About HLB Pharmaceutical Co. Ltd

HLB Pharmaceutical Co., Ltd., a pharmaceutical company, researches and develops peptide drugs in South Korea. The company offers skeletal muscle relaxants, tranquilizers, antihistamines, antihypertensive agents, pain relief, antipruritics, astringents, anti-inflammatories, alimentary system drugs, metabolic drugs, ophthalmic agents, local anesthetics, antiarteriosclerotic agents, expectorants, antipyretics, analgesics, antidiabetic drug, chemotherapeutics, peptic ulcer agents, central nervous system drug, antibiotics, digestives, antacids, dental drugs, multivitamins, parasistic skin disese drugs, dermatlogicals, agents for urogenital organ, amino acid agent, antitussive, mucolytic agents, anthelmintics, antidiarrheals, circulatory system drug, vitamins, skin softeners, anti-hemorrhoid drugs, and agents for liver disease. It is also developing CTT-004 for the treatment of ataxia induced by spinocerebellar degeneration; and offers CMO services. The company was formerly known as Mediforum Pharmaceutical Incorporation and changed its name to HLB Pharmaceutical Co., Ltd in October 2020. HLB Pharmaceutical Co., Ltd. was founded in 1998 and is headquartered in Namyangju-si, South Korea.

Fundamental data was last updated by Penke on 2024-12-09 17:07:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is overpriced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit HLB Pharmaceutical Co. Ltd earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare HLB Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 1.4% means that ₩0.01 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of HLB Pharmaceutical Co. Ltd:

  • The MRQ is 1.4%. The company is making a profit. +1
  • The TTM is -2.5%. The company is making a loss. -1
Trends
Current periodCompared to+/- 
MRQ1.4%TTM-2.5%+3.9%
TTM-2.5%YOY-17.7%+15.2%
TTM-2.5%5Y-43.5%+41.0%
5Y-43.5%10Y-86.7%+43.1%
4.3.1.2. Return on Assets

Shows how efficient HLB Pharmaceutical Co. Ltd is using its assets to generate profit.

  • Above 5% is considered healthy but always compare HLB Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.3% Return on Assets means that HLB Pharmaceutical Co. Ltd generated ₩0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of HLB Pharmaceutical Co. Ltd:

  • The MRQ is 0.3%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is -0.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.3%TTM-0.7%+1.0%
TTM-0.7%YOY-4.0%+3.3%
TTM-0.7%5Y-5.3%+4.6%
5Y-5.3%10Y-4.5%-0.8%
4.3.1.3. Return on Equity

Shows how efficient HLB Pharmaceutical Co. Ltd is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare HLB Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.4% Return on Equity means HLB Pharmaceutical Co. Ltd generated ₩0.00 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of HLB Pharmaceutical Co. Ltd:

  • The MRQ is 0.4%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is -1.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ0.4%TTM-1.1%+1.6%
TTM-1.1%YOY-6.7%+5.6%
TTM-1.1%5Y-12.0%+10.9%
5Y-12.0%10Y-10.1%-2.0%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of HLB Pharmaceutical Co. Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient HLB Pharmaceutical Co. Ltd is operating .

  • Measures how much profit HLB Pharmaceutical Co. Ltd makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare HLB Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of HLB Pharmaceutical Co. Ltd:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y0.7%-0.7%
5Y0.7%10Y-52.2%+52.9%
4.3.2.2. Operating Ratio

Measures how efficient HLB Pharmaceutical Co. Ltd is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.36 means that the operating costs are ₩1.36 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of HLB Pharmaceutical Co. Ltd:

  • The MRQ is 1.359. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.455. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.359TTM1.455-0.095
TTM1.455YOY0.530+0.925
TTM1.4555Y0.711+0.743
5Y0.71110Y1.793-1.082
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of HLB Pharmaceutical Co. Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if HLB Pharmaceutical Co. Ltd is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 2.18 means the company has ₩2.18 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of HLB Pharmaceutical Co. Ltd:

  • The MRQ is 2.183. The company is able to pay all its short-term debts. +1
  • The TTM is 1.704. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.183TTM1.704+0.479
TTM1.704YOY1.106+0.598
TTM1.7045Y1.277+0.426
5Y1.27710Y1.455-0.178
4.4.3.2. Quick Ratio

Measures if HLB Pharmaceutical Co. Ltd is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare HLB Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 1.21 means the company can pay off ₩1.21 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of HLB Pharmaceutical Co. Ltd:

  • The MRQ is 1.206. The company is just able to pay all its short-term debts with the most liquid assets.
  • The TTM is 0.960. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ1.206TTM0.960+0.247
TTM0.960YOY0.944+0.016
TTM0.9605Y1.060-0.101
5Y1.06010Y0.968+0.093
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of HLB Pharmaceutical Co. Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of HLB Pharmaceutical Co. Ltd assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare HLB Pharmaceutical Co. Ltd to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.27 means that HLB Pharmaceutical Co. Ltd assets are financed with 26.7% credit (debt) and the remaining percentage (100% - 26.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of HLB Pharmaceutical Co. Ltd:

  • The MRQ is 0.267. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.327. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.267TTM0.327-0.061
TTM0.327YOY0.400-0.073
TTM0.3275Y0.452-0.125
5Y0.45210Y0.473-0.020
4.5.4.2. Debt to Equity Ratio

Measures if HLB Pharmaceutical Co. Ltd is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare HLB Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 36.3% means that company has ₩0.36 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of HLB Pharmaceutical Co. Ltd:

  • The MRQ is 0.363. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.499. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.363TTM0.499-0.135
TTM0.499YOY0.668-0.170
TTM0.4995Y0.908-0.410
5Y0.90810Y0.971-0.063
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings HLB Pharmaceutical Co. Ltd generates.

  • Above 15 is considered overpriced but always compare HLB Pharmaceutical Co. Ltd to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 285.11 means the investor is paying ₩285.11 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of HLB Pharmaceutical Co. Ltd:

  • The EOD is 371.394. Based on the earnings, the company is expensive. -2
  • The MRQ is 285.109. Based on the earnings, the company is expensive. -2
  • The TTM is 28.317. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD371.394MRQ285.109+86.285
MRQ285.109TTM28.317+256.792
TTM28.317YOY18.845+9.472
TTM28.3175Y25.456+2.862
5Y25.45610Y24.472+0.984
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of HLB Pharmaceutical Co. Ltd:

  • The EOD is 69.792. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The MRQ is 53.577. Based on how much money comes from the company's main activities, the company is overpriced. -1
  • The TTM is 66.133. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD69.792MRQ53.577+16.214
MRQ53.577TTM66.133-12.556
TTM66.133YOY-30.959+97.093
TTM66.1335Y-120.588+186.722
5Y-120.58810Y-90.823-29.765
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of HLB Pharmaceutical Co. Ltd is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 4.90 means the investor is paying ₩4.90 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of HLB Pharmaceutical Co. Ltd:

  • The EOD is 6.384. Based on the equity, the company is overpriced. -1
  • The MRQ is 4.901. Based on the equity, the company is fair priced.
  • The TTM is 6.214. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.384MRQ4.901+1.483
MRQ4.901TTM6.214-1.313
TTM6.214YOY4.711+1.503
TTM6.2145Y7.742-1.528
5Y7.74210Y10.292-2.550
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2024-06-30. Currency in KRW. All numbers in thousands.

Summary
Total Assets157,459,350
Total Liabilities41,973,412
Total Stockholder Equity115,485,939
 As reported
Total Liabilities 41,973,412
Total Stockholder Equity+ 115,485,939
Total Assets = 157,459,350

Assets

Total Assets157,459,350
Total Current Assets81,112,321
Long-term Assets76,347,030
Total Current Assets
Cash And Cash Equivalents 14,230,838
Short-term Investments 26,608,050
Net Receivables 18,209,283
Inventory 20,627,421
Other Current Assets 397,733
Total Current Assets  (as reported)81,112,321
Total Current Assets  (calculated)80,073,325
+/- 1,038,996
Long-term Assets
Property Plant Equipment 46,658,226
Intangible Assets 5,693,215
Long-term Assets  (as reported)76,347,030
Long-term Assets  (calculated)52,351,440
+/- 23,995,589

Liabilities & Shareholders' Equity

Total Current Liabilities37,155,561
Long-term Liabilities4,817,851
Total Stockholder Equity115,485,939
Total Current Liabilities
Short Long Term Debt 15,000,000
Accounts payable 6,918,284
Other Current Liabilities 0
Total Current Liabilities  (as reported)37,155,561
Total Current Liabilities  (calculated)21,918,284
+/- 15,237,277
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,558,400
Long-term Liabilities  (as reported)4,817,851
Long-term Liabilities  (calculated)1,558,400
+/- 3,259,451
Total Stockholder Equity
Total Stockholder Equity (as reported)115,485,939
Total Stockholder Equity (calculated)0
+/- 115,485,939
Other
Capital Stock15,889,997
Common Stock Shares Outstanding 31,746
Net Debt 769,162
Net Invested Capital 130,485,939
Net Working Capital 43,956,760
Property Plant and Equipment Gross 61,751,106



6.2. Balance Sheets Structured

Currency in KRW. All numbers in thousands.

 Trend2024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-30
> Total Assets 
40,818,711
41,432,478
39,846,376
37,353,590
38,547,848
36,981,430
32,635,211
38,018,377
36,486,474
46,394,311
46,976,585
38,760,637
65,343,449
111,419,822
125,138,421
127,161,458
128,009,371
127,632,308
128,164,358
127,914,199
147,885,122
142,177,110
147,852,295
146,005,836
133,051,968
141,351,632
170,633,393
157,459,350
157,459,350170,633,393141,351,632133,051,968146,005,836147,852,295142,177,110147,885,122127,914,199128,164,358127,632,308128,009,371127,161,458125,138,421111,419,82265,343,44938,760,63746,976,58546,394,31136,486,47438,018,37732,635,21136,981,43038,547,84837,353,59039,846,37641,432,47840,818,711
   > Total Current Assets 
20,345,055
20,557,629
23,266,981
21,606,335
22,863,061
21,146,028
17,406,067
20,016,758
18,545,597
29,018,187
27,584,182
20,400,431
46,301,916
94,976,558
63,129,569
52,942,221
56,274,754
51,467,638
53,730,663
40,013,097
60,818,133
59,945,909
63,803,557
56,179,481
51,668,832
71,574,515
79,373,673
81,112,321
81,112,32179,373,67371,574,51551,668,83256,179,48163,803,55759,945,90960,818,13340,013,09753,730,66351,467,63856,274,75452,942,22163,129,56994,976,55846,301,91620,400,43127,584,18229,018,18718,545,59720,016,75817,406,06721,146,02822,863,06121,606,33523,266,98120,557,62920,345,055
       Cash And Cash Equivalents 
2,934,941
1,041,833
5,349,822
218,919
52,727
1,154,452
1,373,763
916,853
2,171,780
2,736,175
5,410,606
3,429,670
29,653,072
14,080,147
18,290,778
2,081
6,504
2,500
813
3,225
3,317
317
2,797
3,697
3,235,021
4,766,318
11,546,731
14,230,838
14,230,83811,546,7314,766,3183,235,0213,6972,7973173,3173,2258132,5006,5042,08118,290,77814,080,14729,653,0723,429,6705,410,6062,736,1752,171,780916,8531,373,7631,154,45252,727218,9195,349,8221,041,8332,934,941
       Short-term Investments 
782,000
615,000
525,000
901,575
160,000
235,000
175,000
295,000
415,000
0
0
0
125,000
65,170,000
25,550,000
25,000,000
25,000,000
18,905,000
15,950,000
995,000
15,040,000
14,880,000
12,500,000
5,500,000
5,500,000
26,608,050
26,608,050
26,608,050
26,608,05026,608,05026,608,0505,500,0005,500,00012,500,00014,880,00015,040,000995,00015,950,00018,905,00025,000,00025,000,00025,550,00065,170,000125,000000415,000295,000175,000235,000160,000901,575525,000615,000782,000
       Net Receivables 
9,119,872
9,617,250
6,521,201
4,491,788
6,459,624
5,594,223
5,613,546
8,040,375
6,261,321
8,066,215
7,922,242
7,722,198
7,747,059
8,333,889
9,900,601
11,567,359
11,918,143
13,039,906
15,677,410
15,876,993
14,134,720
16,676,277
21,567,326
21,185,138
20,144,741
18,584,243
17,925,291
18,209,283
18,209,28317,925,29118,584,24320,144,74121,185,13821,567,32616,676,27714,134,72015,876,99315,677,41013,039,90611,918,14311,567,3599,900,6018,333,8897,747,0597,722,1987,922,2428,066,2156,261,3218,040,3755,613,5465,594,2236,459,6244,491,7886,521,2019,617,2509,119,872
       Inventory 
3,395,295
3,133,028
4,883,833
5,504,343
5,104,534
5,634,146
6,422,585
6,758,906
7,898,532
5,647,885
5,483,040
6,544,512
7,217,999
7,059,228
7,186,648
8,625,784
11,562,828
12,348,183
13,072,501
12,962,455
16,273,986
17,553,420
19,961,949
21,722,770
20,516,050
20,858,115
21,618,701
20,627,421
20,627,42121,618,70120,858,11520,516,05021,722,77019,961,94917,553,42016,273,98612,962,45513,072,50112,348,18311,562,8288,625,7847,186,6487,059,2287,217,9996,544,5125,483,0405,647,8857,898,5326,758,9066,422,5855,634,1465,104,5345,504,3434,883,8333,133,0283,395,295
       Other Current Assets 
126,611
577,938
230,820
787,459
617,567
574,268
535,131
324,558
90,014
93,851
1,314,000
1,377,000
962,000
0
0
550,000
0
0
-645,882
0
0
0
1
107,260
149,698
144,170
439,280
397,733
397,733439,280144,170149,698107,2601000-645,88200550,00000962,0001,377,0001,314,00093,85190,014324,558535,131574,268617,567787,459230,820577,938126,611
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
82,231,200
84,048,738
89,826,355
81,383,136
69,777,117
91,259,721
76,347,030
76,347,03091,259,72169,777,11781,383,13689,826,35584,048,73882,231,200000000000000000000000
       Property Plant Equipment 
13,166,601
13,146,677
13,322,807
13,426,340
13,340,812
13,266,844
13,257,597
15,827,467
15,812,228
15,314,829
17,350,574
16,144,834
16,586,587
8,903,641
52,565,642
53,615,113
54,104,863
53,954,326
53,017,127
53,009,201
52,170,546
51,612,301
51,282,039
49,008,662
48,388,527
48,357,790
48,025,574
46,658,226
46,658,22648,025,57448,357,79048,388,52749,008,66251,282,03951,612,30152,170,54653,009,20153,017,12753,954,32654,104,86353,615,11352,565,6428,903,64116,586,58716,144,83417,350,57415,314,82915,812,22815,827,46713,257,59713,266,84413,340,81213,426,34013,322,80713,146,67713,166,601
       Long Term Investments 
5,383,477
5,796,597
1,789,127
931,281
993,500
1,151,500
1,367,500
1,475,500
1,113,500
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000001,113,5001,475,5001,367,5001,151,500993,500931,2811,789,1275,796,5975,383,477
       Intangible Assets 
346,023
331,844
188,449
198,609
192,455
272,064
280,117
604,419
922,529
1,075,959
1,142,677
1,161,802
1,353,636
1,571,621
1,569,746
2,183,447
2,125,372
2,121,673
2,241,456
2,174,436
2,123,088
2,069,339
2,200,075
3,971,564
3,956,554
5,165,790
5,168,813
5,693,215
5,693,2155,168,8135,165,7903,956,5543,971,5642,200,0752,069,3392,123,0882,174,4362,241,4562,121,6732,125,3722,183,4471,569,7461,571,6211,353,6361,161,8021,142,6771,075,959922,529604,419280,117272,064192,455198,609188,449331,844346,023
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000
> Total Liabilities 
23,620,452
23,430,222
23,044,782
18,912,313
17,578,561
17,014,961
16,242,623
20,545,299
18,092,990
29,035,361
29,498,092
20,025,531
36,778,384
66,797,556
61,397,034
68,779,612
75,546,040
49,247,719
50,103,393
39,744,108
58,192,536
56,248,554
60,061,888
59,361,262
53,074,224
53,198,232
45,489,336
41,973,412
41,973,41245,489,33653,198,23253,074,22459,361,26260,061,88856,248,55458,192,53639,744,10850,103,39349,247,71975,546,04068,779,61261,397,03466,797,55636,778,38420,025,53129,498,09229,035,36118,092,99020,545,29916,242,62317,014,96117,578,56118,912,31323,044,78223,430,22223,620,452
   > Total Current Liabilities 
6,314,732
6,371,876
17,741,176
14,921,006
14,216,004
13,665,761
11,967,770
14,476,884
12,251,801
23,091,634
24,676,629
15,797,960
31,397,108
61,981,251
56,540,892
64,338,196
71,865,149
45,507,258
46,394,081
36,051,634
54,528,902
52,856,816
55,568,078
54,711,425
48,474,075
48,896,086
37,762,904
37,155,561
37,155,56137,762,90448,896,08648,474,07554,711,42555,568,07852,856,81654,528,90236,051,63446,394,08145,507,25871,865,14964,338,19656,540,89261,981,25131,397,10815,797,96024,676,62923,091,63412,251,80114,476,88411,967,77013,665,76114,216,00414,921,00617,741,1766,371,8766,314,732
       Short-term Debt 
16,322,117
505,000
10,388,142
9,159,468
5,016,776
5,039,980
480,000
480,000
1,200,000
1,200,000
1,200,000
1,200,000
500,000
463,630
436,360
409,090
0
0
0
0
0
0
0
0
0
0
0
0
000000000000409,090436,360463,630500,0001,200,0001,200,0001,200,0001,200,000480,000480,0005,039,9805,016,7769,159,46810,388,142505,00016,322,117
       Short Long Term Debt 
16,322,117
505,000
10,388,142
9,159,468
5,016,776
5,039,980
480,000
480,000
780,000
0
0
0
0
0
0
0
0
0
0
0
0
23,779,318
22,779,318
20,835,605
19,500,000
21,760,000
15,200,000
15,000,000
15,000,00015,200,00021,760,00019,500,00020,835,60522,779,31823,779,318000000000000780,000480,000480,0005,039,9805,016,7769,159,46810,388,142505,00016,322,117
       Accounts payable 
2,890,848
2,924,181
2,260,910
1,881,376
2,791,994
2,953,431
6,002,429
4,443,118
3,337,544
2,404,327
0
0
0
0
0
0
0
0
0
0
0
7,889,282
11,770,045
9,009,723
7,215,607
6,960,222
6,684,975
6,918,284
6,918,2846,684,9756,960,2227,215,6079,009,72311,770,0457,889,282000000000002,404,3273,337,5444,443,1186,002,4292,953,4312,791,9941,881,3762,260,9102,924,1812,890,848
       Other Current Liabilities 
1,369,898
1,004,063
1,125,926
1,002,826
1,738,952
2,444,032
3,441,111
2,834,640
2,879,520
6,429,253
0
0
0
0
0
0
0
0
0
0
0
1
1
1
-1
0
1
0
010-1111000000000006,429,2532,879,5202,834,6403,441,1112,444,0321,738,9521,002,8261,125,9261,004,0631,369,898
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,391,738
4,493,810
4,649,836
4,600,149
4,302,146
7,726,432
4,817,851
4,817,8517,726,4324,302,1464,600,1494,649,8364,493,8103,391,738000000000000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
3,929,007
3,533,514
3,477,841
2,974,908
4,225,147
3,855,153
3,762,588
2,232,330
2,312,142
2,139,025
1,952,858
1,831,729
1,637,374
1,655,815
2,582,968
1,475,794
0
0
0
0
00001,475,7942,582,9681,655,8151,637,3741,831,7291,952,8582,139,0252,312,1422,232,3303,762,5883,855,1534,225,1472,974,9083,477,8413,533,5143,929,00700000000
       Capital Lease Obligations 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,571,625
2,585,498
2,460,413
2,252,862
1,967,568
1,799,083
1,558,400
1,558,4001,799,0831,967,5682,252,8622,460,4132,585,4982,571,625000000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000
       Deferred Long Term Liability 
433,428
508,710
0
0
0
0
149,482
0
0
629,759
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000629,75900149,4820000508,710433,428
> Total Stockholder Equity
17,198,258
18,002,256
16,801,594
16,801,594
20,969,287
19,966,469
16,392,588
17,473,078
18,393,484
17,358,951
17,478,494
18,735,107
28,565,066
44,622,266
63,741,387
58,381,846
52,463,332
78,384,589
78,060,965
88,170,091
89,692,586
85,928,556
87,790,407
86,644,574
79,977,745
88,153,400
125,144,056
115,485,939
115,485,939125,144,05688,153,40079,977,74586,644,57487,790,40785,928,55689,692,58688,170,09178,060,96578,384,58952,463,33258,381,84663,741,38744,622,26628,565,06618,735,10717,478,49417,358,95118,393,48417,473,07816,392,58819,966,46920,969,28716,801,59416,801,59418,002,25617,198,258
   Common Stock
5,920,009
6,011,695
6,246,586
6,504,181
6,924,187
6,924,187
6,924,187
6,924,187
6,924,187
6,924,187
6,924,187
7,021,436
9,113,692
10,495,727
11,178,911
11,178,911
11,178,911
13,049,091
13,312,466
13,782,132
13,935,575
13,935,575
14,017,182
14,802,051
0
0
0
0
000014,802,05114,017,18213,935,57513,935,57513,782,13213,312,46613,049,09111,178,91111,178,91111,178,91110,495,7279,113,6927,021,4366,924,1876,924,1876,924,1876,924,1876,924,1876,924,1876,924,1876,504,1816,246,5866,011,6955,920,009
   Retained Earnings Total Equity0000000000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000000000
   Capital Surplus 
0
0
0
0
0
0
0
0
9,769,624
9,769,624
9,769,624
10,662,375
27,329,155
108,253,264
129,996,963
129,862,580
129,862,580
150,169,104
67,078,695
76,862,365
81,453,994
81,453,994
82,370,811
92,077,821
0
0
0
0
000092,077,82182,370,81181,453,99481,453,99476,862,36567,078,695150,169,104129,862,580129,862,580129,996,963108,253,26427,329,15510,662,3759,769,6249,769,6249,769,62400000000
   Treasury Stock0000000000-5,600-5,600-5,600-5,600-5,600-5,600-5,600-5,600-5,600-5,60000000000
   Other Stockholders Equity 
529,238
824,289
707,132
909,605
1,016,497
1,123,389
1,334,142
1
1,334,143
1,334,143
0
0
0
0
0
0
0
0
0
-1
-1
0
1
0
0
0
0
0
0000010-1-10000000001,334,1431,334,14311,334,1421,123,3891,016,497909,605707,132824,289529,238



6.3. Balance Sheets

Currency in KRW. All numbers in thousands.




6.4. Cash Flows

Currency in KRW. All numbers in thousands.




6.5. Income Statements

Currency in KRW. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in KRW. All numbers in thousands.

Gross Profit (+$)
totalRevenue135,952,754
Cost of Revenue-52,967,405
Gross Profit82,985,34982,985,349
 
Operating Income (+$)
Gross Profit82,985,349
Operating Expense-155,494,942
Operating Income-19,542,188-72,509,593
 
Operating Expense (+$)
Research Development2,305,291
Selling General Administrative92,942,079
Selling And Marketing Expenses0
Operating Expense155,494,94295,247,370
 
Net Interest Income (+$)
Interest Income403,434
Interest Expense-11,767,368
Other Finance Cost-196,992
Net Interest Income-11,166,942
 
Pretax Income (+$)
Operating Income-19,542,188
Net Interest Income-11,166,942
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-18,851,392-19,542,188
EBIT - interestExpense = -11,767,368
-19,427,453
-7,660,085
Interest Expense11,767,368
Earnings Before Interest and Taxes (EBIT)0-7,084,024
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-18,851,392
Tax Provision-576,061
Net Income From Continuing Ops-19,427,453-19,427,453
Net Income-19,427,453
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net011,166,942
 

Technical Analysis of HLB Pharmaceutical Co. Ltd
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of HLB Pharmaceutical Co. Ltd. The general trend of HLB Pharmaceutical Co. Ltd is BEARISH with 28.6% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine HLB Pharmaceutical Co. Ltd's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-28.6%) Bearish trend (28.6%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of HLB Pharmaceutical Co. Ltd.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 25,350 < 25,350 < 25,750.

The bearish price targets are: 20,350 > 16,920 > 15,940.

Tweet this
HLB Pharmaceutical Co. Ltd Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of HLB Pharmaceutical Co. Ltd. The current mas is .

The long score for the Moving Averages is 5/14.
The longshort score for the Moving Averages is -4/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

HLB Pharmaceutical Co. Ltd Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of HLB Pharmaceutical Co. Ltd. The current macd is 455.22.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the HLB Pharmaceutical Co. Ltd price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for HLB Pharmaceutical Co. Ltd. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the HLB Pharmaceutical Co. Ltd price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
HLB Pharmaceutical Co. Ltd Daily Moving Average Convergence/Divergence (MACD) ChartHLB Pharmaceutical Co. Ltd Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of HLB Pharmaceutical Co. Ltd. The current adx is 31.48.

The long score for the Directional Movement Index (DMI) is 4/7.
The longshort score for the Directional Movement Index (DMI) is 4/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy HLB Pharmaceutical Co. Ltd shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bullish trend. The ADX is trending up, so the bullish trend is strengthening.
HLB Pharmaceutical Co. Ltd Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of HLB Pharmaceutical Co. Ltd. The current sar is 24,382.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
HLB Pharmaceutical Co. Ltd Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of HLB Pharmaceutical Co. Ltd. The current rsi is 59.90. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
HLB Pharmaceutical Co. Ltd Daily Relative Strength Index (RSI) ChartHLB Pharmaceutical Co. Ltd Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of HLB Pharmaceutical Co. Ltd. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the HLB Pharmaceutical Co. Ltd price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
HLB Pharmaceutical Co. Ltd Daily Stochastic Oscillator ChartHLB Pharmaceutical Co. Ltd Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of HLB Pharmaceutical Co. Ltd. The current cci is 80.43.

HLB Pharmaceutical Co. Ltd Daily Commodity Channel Index (CCI) ChartHLB Pharmaceutical Co. Ltd Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of HLB Pharmaceutical Co. Ltd. The current cmo is 28.36.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
HLB Pharmaceutical Co. Ltd Daily Chande Momentum Oscillator (CMO) ChartHLB Pharmaceutical Co. Ltd Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of HLB Pharmaceutical Co. Ltd. The current willr is -21.91780822.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that HLB Pharmaceutical Co. Ltd is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
HLB Pharmaceutical Co. Ltd Daily Williams %R ChartHLB Pharmaceutical Co. Ltd Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of HLB Pharmaceutical Co. Ltd.

HLB Pharmaceutical Co. Ltd Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of HLB Pharmaceutical Co. Ltd. The current atr is 1,205.

HLB Pharmaceutical Co. Ltd Daily Average True Range (ATR) ChartHLB Pharmaceutical Co. Ltd Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of HLB Pharmaceutical Co. Ltd. The current obv is 111,899,465.

HLB Pharmaceutical Co. Ltd Daily On-Balance Volume (OBV) ChartHLB Pharmaceutical Co. Ltd Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of HLB Pharmaceutical Co. Ltd. The current mfi is 65.66.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
HLB Pharmaceutical Co. Ltd Daily Money Flow Index (MFI) ChartHLB Pharmaceutical Co. Ltd Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for HLB Pharmaceutical Co. Ltd.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-07-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-30STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-07-31MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-08-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-06STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-08-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-08-13WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-08-20STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-08-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-08-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-08-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-08-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-08-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-08-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-08-30DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-06STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-09MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-09-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-09-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-09-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-20CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-09-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-09-25MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-09-26DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-09-27WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-09-30CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-02BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-04STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-08BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-16MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-21RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-10-29STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-31RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-01STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-13STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-14MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-18DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-19MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-22BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-11-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-28MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-03MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-12-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-12-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-11CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-13CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-18WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-19STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

HLB Pharmaceutical Co. Ltd Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of HLB Pharmaceutical Co. Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5059.898
Ma 20Greater thanMa 5022,280.000
Ma 50Greater thanMa 10020,783.600
Ma 100Greater thanMa 20023,564.300
OpenGreater thanClose22,800.000
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of HLB Pharmaceutical Co. Ltd with someone you think should read this too:
  • Are you bullish or bearish on HLB Pharmaceutical Co. Ltd? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about HLB Pharmaceutical Co. Ltd? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about HLB Pharmaceutical Co. Ltd

I send you an email if I find something interesting about HLB Pharmaceutical Co. Ltd.


Comments

How you think about this?

Leave a comment

Stay informed about HLB Pharmaceutical Co. Ltd.

Receive notifications about HLB Pharmaceutical Co. Ltd in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.